5C-D

5C-D, also known as 4-methyl-2,5-dimethoxy-α-propylphenethylamine, is a putatively non-hallucinogenic serotonin 5-HT₂ receptor agonist of the phenethylamine and α-propylphenethylamine families related to the 4C drug Ariadne (4C-D).^{[1] [2]}

At the serotonin 5-HT_2A receptor, 5C-D is a potent and higher-efficacy partial agonist, with an EC₅₀ Tooltip half-maximal effective concentration of 291 nM and an E_max Tooltip maximal efficacy of 69%.^{[1] [2]} It is about half as potent as Ariadne as a serotonin 5-HT_2A receptor agonist and has about 15% lower efficacy in activating the receptor in comparison.^{[1] [2]} 5C-D has also been shown to be a serotonin 5-HT_2B receptor agonist.^[2] In contrast to Ariadne and serotonergic psychedelics, 5C-D does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.^[2]

5C-D was first described in the scientific literature by Michael Cunningham and colleagues by 2023.^[2] It was synthesized and assessed during structure–activity relationship (SAR) studies of Ariadne.^{[1] [2]}

• Substituted methoxyphenethylamine
• Non-hallucinogenic 5-HT_2A receptor agonist
• 4C and Ariadne (4C-D)
• α-Propylmescaline (APM)

• 5C-D - Isomer Design

• Drugs not assigned an ATC code
• 5-HT2B agonists
• Alpha-Propylphenethylamines
• Methoxyphenethylamines
• Methyl compounds
• Non-hallucinogenic 5-HT2A receptor agonists

• Articles with short description
• Short description matches Wikidata
• Chemical articles without CAS registry number
• Articles without EBI source
• Chemical pages without ChemSpiderID
• Chemical pages without DrugBank identifier
• Articles without KEGG source
• Articles without UNII source
• Drugs with no legal status
• Articles containing unverified chemical infoboxes